Januvia and Byetta, two common diabetes drugs, may double the risk of developing pancreatitis, says a new study from researchers at Johns Hopkins University. The drugs are sold by Merck and Bristol-Meyers Squibb/Astra-Zeneca, respectively.
For the study lead researcher Sonal Singh and his colleagues reviewed insurance records and found that those hospitalized for pancreatitis were twice as likely to be taking either of the two drugs.
"This is the first real study to give an estimate of what the risk is," Singh told Bloomberg earlier this week. "[U]ntil now we just had a few case reports."
The FDA has previously flagged both of these medications as possible contributors to pancreatitis. They also added new warnings to the Byetta label after six patient deaths were linked to the drug in 2008.
by RTT Staff Writer
For comments and feedback: email@example.com